CN Patent

CN112292132A — 含有双重nk-1/nk-3受体拮抗剂的新颖的药物制剂

Assigned to Kandy Therapeutics Ltd · Expires 2021-01-29 · 5y expired

What this patent protects

本发明大体涉及新颖的药物制剂、其制备方法以及它们在药物疗法中的用途，所述药物制剂含有2‑[3,5‑双(三氟甲基)苯基]‑N‑{4‑(4‑氟‑2‑甲基苯基)‑6‑[(7S,9aS)‑7‑(羟基甲基)六氢吡嗪并[2,1‑c][1,4]噁嗪‑8(1H)‑基]‑3‑吡啶基}‑N,2‑二甲基丙酰胺。

USPTO Abstract

本发明大体涉及新颖的药物制剂、其制备方法以及它们在药物疗法中的用途，所述药物制剂含有2‑[3,5‑双(三氟甲基)苯基]‑N‑{4‑(4‑氟‑2‑甲基苯基)‑6‑[(7S,9aS)‑7‑(羟基甲基)六氢吡嗪并[2,1‑c][1,4]噁嗪‑8(1H)‑基]‑3‑吡啶基}‑N,2‑二甲基丙酰胺。

Drugs covered by this patent

Patent Metadata

Patent number
CN112292132A
Jurisdiction
CN
Classification
—
Expires
2021-01-29
Drug substance claim
No
Drug product claim
No
Assignee
Kandy Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.